PNC-27 is one of the most mechanistically unusual compounds in research-vendor catalogues — and one of the most important to frame carefully. It is an experimental anticancer peptide that kills transformed cells not through the classical p53 tumour-suppressor transcription programme, but by punching selective pores in the cancer-cell membrane. It is a purely preclinical research molecule with no approved use and no established human safety data, and this monograph treats it accordingly: what it is, the membrane-HDM-2 mechanism that makes it selective, the (entirely laboratory) evidence base, and the heavy caveats a researcher must keep in view.
Chemical identity and structure.
PNC-27 is a 32-residue chimeric peptide. It joins the HDM-2-binding domain of the p53 protein (residues 12–26) to a cell-penetrating "leader" sequence — the penetratin peptide derived from the Antennapedia homeodomain. The p53 fragment supplies target recognition; the penetratin segment supplies membrane interaction.
Mechanism of action.
PNC-27's selectivity is the headline. Cancer cells frequently express HDM-2 (the human homologue of MDM2) in their plasma membrane; normal, untransformed cells generally do not. PNC-27 binds this membrane-bound HDM-2 in a p53-peptide-like conformation and induces the formation of transmembrane pores, leading to tumour-cell lysis and necrosis. Immuno-scanning electron microscopy has visualised ring-shaped, gold-labelled complexes in the pores, supporting a 1:1 PNC-27:HDM-2 pore model. The peptide has also been reported to disrupt mitochondrial membranes. Crucially, no pores form in PNC-27-treated normal fibroblasts, which lack membrane HDM-2 — this is the mechanistic basis for the compound's reported cancer selectivity. The killing is necrotic and membrane-mediated, not the transcription-dependent apoptosis usually associated with p53.
Research applications and the evidence base.
PNC-27 has been studied in vitro and in animal models across several cancers, including leukaemia and solid-tumour lines, with reported activity in cervical-cancer and other models. The entire evidence base is preclinical. There is no FDA approval, no completed human efficacy trial, and no established human safety profile. Any discussion of PNC-27 should foreground this: it is a research tool for studying membrane-HDM-2 biology and selective cytolysis, not a treatment.
Human clinical trial data.
No human clinical trial has established administration parameters for PNC-27; VialTalk does not provide community-sourced dosing.
Storage and handling.
Store lyophilized PNC-27 at −20 °C or colder (−80 °C is ideal for long-term), dry and dark; short-term refrigeration at 2–8 °C is acceptable for days to weeks. Avoid freeze–thaw.
Quality and COA considerations.
A meaningful COA should confirm identity by mass spectrometry against the 32-residue mass, report purity by HPLC (≥95–98% is a reasonable benchmark for a peptide of this length, where synthesis truncations are common), report residual TFA (a synthesis counter-ion), and — because the research uses involve membranes and cells — report endotoxin. Purity matters more than usual here: truncated synthesis by-products of a pore-forming peptide are an obvious confounder in any cytolysis assay.
Research-use note: This monograph is an educational summary of the published preclinical literature for PNC-27, a chimeric p53-penetratin peptide. PNC-27 is for laboratory and research use only. It has no FDA approval, no completed human efficacy trial, and no established human safety data; none of the figures above is a therapy, a dose recommendation, or a clinical protocol, and nothing here is medical advice.
